What's Happening?
The FDA has approved bemotrizinol for use in U.S. sunscreens, marking the first new sunscreen ingredient approval since the 1990s. Bemotrizinol, already popular in Europe, offers broad-spectrum protection against UVA and UVB rays and is more photostable
than existing ingredients. The approval was expedited under the CARES Act, aiming to improve consumer access to effective sun protection. The ingredient is expected to be available in U.S. products starting August 2026, initially through DSM Nutritional Products, with broader availability following an 18-month exclusivity period.
Why It's Important?
This approval is a major step forward in aligning U.S. sunscreen standards with international practices, potentially reducing skin cancer rates and improving public health. The introduction of bemotrizinol is expected to enhance consumer confidence in sunscreen efficacy and safety. The decision also highlights the impact of regulatory reforms aimed at streamlining the approval process for over-the-counter drugs, which could lead to further innovations in the skincare industry. The availability of more effective sunscreens may encourage greater use among consumers, contributing to better skin health outcomes.
What's Next?
Manufacturers can begin incorporating bemotrizinol into their products starting in August 2026. DSM Nutritional Products will initially have exclusive rights to the ingredient, with other companies expected to follow suit after the exclusivity period. The market is likely to see an influx of new sunscreen products featuring bemotrizinol, offering consumers enhanced protection options. Dermatologists and health organizations will continue to advocate for the use of advanced sunscreen formulations to improve public health outcomes.
